Turn Therapeutics Inc. TTRX
Turn Therapeutics Inc. (Nasdaq: TTRX) is a dermatology drug developer. Its lead program, GX-03, is in Phase 2 for Atopic dermatitis / moderate-to-severe eczema (topical PHMB-based immunomodulator). Its next catalyst on record is GX-03 (hidradenitis suppurativa): Initiation of Phase 2a study (June 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: GX-03 (hidradenitis suppurativa) — Initiation of Phase 2a study (June 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GX-03 | Atopic dermatitis (randomized, double-blind, vehicle-controlled adaptive Phase 2; Stage 2 expansion enrolling) | small molecule | Phase 2 |
| GX-03 | Onychomycosis (animal-model data; clinical steps to follow AD program and IND activities) | small molecule | Pre-clinical |
| GX-03 | Hidradenitis suppurativa (animal/in vitro data) | small molecule | Pre-clinical |
| Thermostable intranasal vaccine platform | Exploratory, not primary path | vaccine | Pre-clinical |
Recent results and decisions
- Jul 7, 2026positive Stage 1 interim analysis subgroup (EASI>=1.1, PP-NRS>=7) showed GX-03 vs vehicle: Week 4 vIGA-AD success 61.5% vs 8.3%, Week 4 EASI-75 69.2% vs 25.0%, Week 8 EASI-90 53.8% vs 16.7%, Week 8 EASI-100 46.2% vs 8.3% (n=13 vs 12); no formal primary endpoint or p-values.
Applying the final Stage 2 enrollment criteria to the completed interim analysis population demonstrated notable statistical separation from vehicle across all four prespecified efficacy endpoints.
Filing - Jun 1, 2026positive Interim (first 50 subjects) Phase 2 GX-03: EASI-50 at week 4 92.6% vs 65.2% vehicle; EASI-90 week 8 51.9% vs 34.8%; no treatment-related SAEs.
Within the completed interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in overall eczema severity within 4 weeks (EASI-50) compared to 65.2% for vehicle-treated subjects.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.